The 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice were developed by the Task Force for cardiovascular disease prevention in clinical practice, with representatives from the European Society of Cardiology and 12 medical societies. The guidelines aim to assist health professionals in making the best management decisions for individual patients and at a population level. They emphasize the importance of risk assessment, risk classification, and prevention strategies, including lifestyle modifications, pharmacological treatments, and patient education. The guidelines also address the impact of various risk factors such as cholesterol, blood pressure, diabetes, smoking, and air pollution on cardiovascular disease (CVD) risk. They provide recommendations for the prevention and management of CVD, including the use of lifestyle interventions, drug treatments, and risk factor control. The guidelines also highlight the importance of personalized treatment approaches, considering individual patient characteristics, and the need for shared decision-making between patients and healthcare professionals. The guidelines are supported by a range of collaborating societies and include detailed recommendations on various aspects of CVD prevention, including risk assessment, risk communication, and the management of specific clinical conditions. The guidelines emphasize the importance of cost-effectiveness, the need for regular follow-up, and the importance of integrating interdisciplinary approaches in CVD prevention. The guidelines also address the impact of environmental factors, such as air pollution and climate change, on CVD risk and prevention. Overall, the guidelines provide a comprehensive framework for the prevention and management of CVD, emphasizing the importance of individualized, evidence-based approaches to care.The 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice were developed by the Task Force for cardiovascular disease prevention in clinical practice, with representatives from the European Society of Cardiology and 12 medical societies. The guidelines aim to assist health professionals in making the best management decisions for individual patients and at a population level. They emphasize the importance of risk assessment, risk classification, and prevention strategies, including lifestyle modifications, pharmacological treatments, and patient education. The guidelines also address the impact of various risk factors such as cholesterol, blood pressure, diabetes, smoking, and air pollution on cardiovascular disease (CVD) risk. They provide recommendations for the prevention and management of CVD, including the use of lifestyle interventions, drug treatments, and risk factor control. The guidelines also highlight the importance of personalized treatment approaches, considering individual patient characteristics, and the need for shared decision-making between patients and healthcare professionals. The guidelines are supported by a range of collaborating societies and include detailed recommendations on various aspects of CVD prevention, including risk assessment, risk communication, and the management of specific clinical conditions. The guidelines emphasize the importance of cost-effectiveness, the need for regular follow-up, and the importance of integrating interdisciplinary approaches in CVD prevention. The guidelines also address the impact of environmental factors, such as air pollution and climate change, on CVD risk and prevention. Overall, the guidelines provide a comprehensive framework for the prevention and management of CVD, emphasizing the importance of individualized, evidence-based approaches to care.